The total profit for the first three years of the "profit test" shall not be less than HKD 50 million, and the profit for the most recent year shall not be less than HKD 20 million; Starting from 2022, the standard will be adjusted to a total of no less than 80 million Hong Kong stocks over three years, with a net profit of no less than 35 million Hong Kong dollars in the most recent year.
At the time of listing, the market value/revenue/cash flow test shall not be less than HKD 2 billion; And the main business sales revenue in the most recent year before listing shall not be less than HKD 500 million; and the net operating cash flow in the three years before listing shall not be less than HKD 100 million.
The total market value at the time of listing shall not be less than HKD 4 billion, and the main business sales revenue in the most recent year before listing shall not be less than HKD 500 million.
Biotechnology companies and companies with the same stock but different rights shall be subject to separate regulations

Test 1: A pre tax sustained business profit of at least $1 million (in the most recent fiscal year or two of the past three fiscal years), and shareholder equity of at least $15 million.
The shareholder equity of Test 2 must reach at least 30 million US dollars and have at least 2 years of operating history.
The total market value of "Test Three" should be at least 75 million US dollars; Or the total assets and total revenue should be at least 75 million US dollars each.